


**Supplementary Figure 1.** Mean ear pinna thickness of mice (n = 4) exposed to FLG or GO (0.01, 0.10 or 1.00 mg/ear) in comparison to that of the negative control (vehicle; 60% PEG) and positive controls (25% eugenol or 1% DNCB) at Day 0 (pre-dose), Day 2 (48 h after the first dose) and Day 5 (3 days after the last treatment).



**Supplementary Figure 2.** Individual weights (mg) of mice at start of dosing and at scheduled humane kill as well as mean and associated error terms (standard deviation, SD; standard error of the mean, SEM) for each treatment group.

<b>Vehicle</b>	#1	#2	#3	#4	<b>MEAN</b>	<b>SD</b>	<b>SEM</b>	<b>Eugenol 25%</b>			<b>MEAN</b>	<b>SD</b>	<b>SEM</b>		
<b>Day 0</b>	20	19	20	21	<b>20,0</b>	0,8	0,4	<b>Day 0</b>	19	20	19	20	<b>19,5</b>	0,6	0,3
<b>Day 5</b>	21	20	20	21	<b>20,5</b>	0,6	0,3	<b>Day 5</b>	20	19	19	20	<b>19,5</b>	0,6	0,3
								<b>DNCB 1%</b>							
								<b>Day 0</b>	20	18	18	19	<b>18,8</b>	1,0	0,5
								<b>Day 5</b>	21	19	20	20	<b>20,0</b>	0,8	0,4
<b>FLG 0.01 mg/ear</b>					<b>MEAN</b>	<b>SD</b>	<b>SEM</b>	<b>GO 0.01 mg/ear</b>			<b>MEAN</b>	<b>SD</b>	<b>SEM</b>		
<b>Day 0</b>	21	19	20	20	<b>20,0</b>	0,8	0,4	<b>Day 0</b>	19	21	20	18	<b>19,5</b>	1,3	0,6
<b>Day 5</b>	21	19	21	22	<b>20,8</b>	1,3	0,6	<b>Day 5</b>	20	22	20	18	<b>20,0</b>	1,6	0,8
<b>FLG 0.1 mg/ear</b>								<b>GO 0.1 mg/ear</b>							
<b>Day 0</b>	18	19	18	18	<b>18,3</b>	0,5	0,3	<b>Day 0</b>	19	20	19	22	<b>20,0</b>	1,4	0,7
<b>Day 5</b>	19	20	20	19	<b>19,5</b>	0,6	0,3	<b>Day 5</b>	21	20	20	24	<b>21,3</b>	1,9	0,9
<b>FLG 1 mg/ear</b>								<b>GO 1 mg/ear</b>							
<b>Day 0</b>	20	20	21	19	<b>20,0</b>	0,8	0,4	<b>Day 0</b>	18	19	20	21	<b>19,5</b>	1,3	0,6
<b>Day 5</b>	22	20	22	19	<b>20,8</b>	1,5	0,8	<b>Day 5</b>	19	21	21	21	<b>20,5</b>	1,0	0,5

**Supplementary Figure 3.** Visual observations of mice ear performed at Day 5 (3 days after the last treatment) on sacrificed mice and related ear punches (bottom panel). Visual inspection were made to identify signs of erythema used to evaluate irritation potential by erythema scoring as defined by the OECD TG 442B.

